David Twibell, president and founder of the Custom Portfolio Group, weighs in on the stock of Ultragenyx Pharmaceutical. Ultragenix is a biotech company focused on the treatment of rare and super-rare diseases, and one of eight companies “joining Netlflix in sky-high territory” on Wall Street.

And now, airing exclusively on Netflix: The drama of a company with a skyrocketing stock price, but facing split opinion about whether it’s an investment gamble going forward.

More accurately, it’s a story exclusively about Netflix stock (ticker: NFLX), which is trading at all-time highs after the company reported second-quarter earnings on Wednesday that trounced Wall Street’s lofty expectations. That pushed NFLX stock – already fresh off a gaudy 7-for-1 split – past $115 on Thursday, up more than 18 percent. And keep in mind that this is a stock that more than doubled just this year, running its stock price from $350 to better than $700 per share before Netflix executed its extraordinary stock split.

Continue reading→